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HBV-related liver diseasesHepatitis E virus (HEV) infection may cause acute hepatitis and lead to hepatic failure in developing and devel-
oped countries.We studiedHEV seroprevalences in patients with hepatitis B virus (HBV) infection to understand
the consequences of HEV superinfection in a Vietnamese population. This cross-sectional study was conducted
from 2012 to 2013 and included 1318 Vietnamese patients with HBV-related liver diseases and 340 healthy
controls. The case group included patients with acute (n = 26) and chronic hepatitis B (n = 744), liver cir-
rhosis (n = 160), hepatocellular carcinoma (n= 166) and patients with both liver cirrhosis and hepatocel-
lular carcinoma (n = 222). Anti-HEV IgG and IgM antibodies were assessed in patients and controls by
ELISA. HEV-RNAwas identiﬁed by PCR assays and sequencing. Seroprevalences of anti-HEV IgG among hep-
atitis B patients and controls were 45% and 31%, respectively (adjusted P = 0.034). Anti-HEV IgM
seroprevalences were 11.6% and 4.7% in patients and controls, respectively (adjusted P = 0.005).
Seroprevalences were higher among the elder individuals. When stratifying for patient groups, those
with liver cirrhosis had the highest anti-HEV IgG (52%) and anti-HEV IgM (19%) seroprevalences. Hepatitis
B patients with current HEV infection had abnormal liver function tests compared to patients with past or
without HEV infection. One HEV isolate was retrieved from a patient with both liver cirrhosis and hepato-
cellular carcinoma and identiﬁed as HEV genotype 3. This study indicates high prevalences of HEV infection
in Vietnamese HBV patients and among healthy individuals and shows that HEV superinfection may inﬂu-
ence the outcome and progression of HBV-related liver disease.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatitis E virus (HEV) may cause acute hepatitis. Pregnant women
are vulnerable to fulminant courses (Boccia et al., 2006; Hamid et al.,
2002). Chronic HEV infectionmay occur mainly in immunocompromised
patients with HIV, organ transplants and during cancer chemotherapyB virus; AHB, acute hepatitis B;
llular carcinoma; IgG, immuno-
frame; WBC, white blood cells;
transferase; ALT, alanine amino
cine, Wilhelmstraße 27, 72074
.P. Velavan).
. This is an open access article under(Dalton et al., 2009; Kamar et al., 2008). Large hepatitis E outbreaks
with 120,000 cases occurred in China in 1986–1988 (Dalton et al.,
2013), followed by N30,000 cases in India in 1956 (Shukla et al., 2011).
Global annual incidences are 20 million asymptomatic infections and
3.4 million acute cases with 70,000 deaths (Rein et al., 2012).
Seroprevalences of 16 to 52% and incidences between 0.2 to 1.7% are
reported from regions with poor sanitation (Dalton et al., 2013). More
than 60% of infections and 65% of deaths occur in Asia, where
seroprevalences exceed 25% in certain age groups (WHO, 2014). The
ﬁrst vaccine for HEVwas licensed in China in 2011 and very recently a re-
combinant HEV vaccine (Hecolin) sustained protection against HEV for
up to 4.5 years after ﬁrst vaccination tested in a Chinese population
(Zhang et al., 2015).
HEV is a hepevirus of 27–34 nm in size (Kamar et al., 2012). Its ge-
nome consists of ssRNA of 7.2 kb, containing three open reading framesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cation while ORF2 and ORF3 encode the capsid and a multifunctional
protein, respectively. However, viral replication in hepatocytes is not
fully understood (Cao and Meng, 2012). Four HEV genotypes have
been identiﬁed. Genotypes 1 and 2 (HEV1, HEV2) only infect humans,
and HEV genotypes 3 and 4 (HEV3, HEV4) can cause human and animal
disease (Kamar et al., 2012, 2014). HEV1 is widely distributed in Asia
and HEV2 predominates in Africa and Mexico. HEV3 and HEV4 are dis-
tributed globally. HEV1, HEV2 and HEV4 are transmitted fecal–orally,
while HEV3 infections occur also by consumption of undercooked
meat (Kamar et al., 2012).
Hepatitis B virus (HBV) infections are frequent in sub-Saharan Africa
and Asia with infection rates between 8% and 20% (WHO, 2013). In
Vietnam, approximately 10 million (10%) individuals live with chronic
hepatitis B (Dunford et al., 2012; Nguyen, 2012). HEV superinfection
in patients with chronic HBV or HCV infections and autoimmune
hepatitis has been found associated with clinical outcomes in several
geographical settings (Atiq et al., 2009; Bayram et al., 2007; Cheng
et al., 2013; Marion-Audibert et al., 2010; Monga et al., 2004; Pischke
et al., 2014). This study aims to assess prevalences and consequences
of HEV infection in patients with HBV-related liver diseases and to com-
pare it to uninfected Vietnamese controls.
2. Materials and Methods
2.1. Study Design and Sample Collection
A cross-sectional study was implemented between June 2012 and
December 2013. A total of 1318 HBV patients and 340 healthy controls
were recruited (108 Military Central Hospital and 103 Hospital of the
VietnamMilitary Medical University, Hanoi). Based on clinical manifes-
tations and laboratory parameters, patients were assigned to the differ-
ent clinical subgroups as previously described (Song et al., 2003).
Brieﬂy, the acute hepatitis B (AHB, n = 26) are patients who presented
with the prodromal symptoms preceded the onset of jaundice (e.g.
fever, anorexia, nausea, vomiting, and fatigue), an onset of clinical jaun-
dice, the constitutional prodromal symptomswere diminished, hepato-
megaly, jaundice, hyperbilirubinemia, serum ALT, and AST at least 5-
fold higher than normal range, HBsAg positive, anti-HBc IgM positive,
anti-HBc IgG negative. The chronic hepatitis B (CHB, n = 744) were
characterized based upon clinical syndromes such as fatigue, anorexia,
jaundice, hepatomegaly, hard density of the liver, splenomegaly,
hyperbilirubinemia, elevated levels of AST and ALT, HBsAg positive for
longer than 6 months. The HBV-related liver cirrhosis (LC, n = 160)
were characterized as patients infected with HBV (HBsAg positive)
showing the clinical manifestations such as anorexia, nausea, vomiting,
malaise, weight loss, abdominal distress, jaundice, edema, cutaneous
arterial “Spider” angiomas, palma erythema, ascites, shrunken liver,
splenomegaly, hyperbilirubinemia, elevated levels of AST and ALT,
prolonged serum prothrombin time, and decreased serum albumin.
The HBV-related hepatocellular carcinoma (HCC, n = 166) were
characterized as patients infected with chronically HBV (HBsAg pos-
itive), abdominal pain, an abdominal mass in the right upper quad-
rant, blood-tinged ascites, weight loss, anorexia, fatigue, jaundice,
prolonged serum prothrombin time, hyperbilirubinemia, elevated
levels of AST, ALT and serum a-fetoprotein (AFP), ultrasound showed
tumor, liver biopsy and histopathology showing tumor cells. The pa-
tients with liver cirrhosis and hepatocellular carcinoma (LC + HCC,
n= 222) were characterized if the patients showed clinical manifes-
tations and laboratory tests of both LC and HCC. In addition, the pa-
tients with LC were also categorized as Child-A, Child-B and Child-C
based on Child–Pugh scores (Cholongitas et al., 2005). We also in-
cluded 340 healthy individuals without any history of alcohol or
drug use as healthy controls (HC). Biochemical and serological tests
were performed for all participants. HBV viral loads were measured
by quantitative real-time PCR as described previously (Song et al.,2003). Five milliliters of venous blood was collected from all partic-
ipants. Serum or plasma was used for biochemical and laboratory
assays.2.2. Ethics Statement
Informed consent was obtained at sampling from all participants or
from parents if subjects were b18 years. The studywas approved by the
institutional review board of the 108 Military Central Hospital and the
103 Military Hospital, Hanoi, Vietnam.2.3. Serology Testing for HEV Infection
Anti-HEV IgG and IgM levels were determined in serum from
patients and healthy controls through ELISA kits (MP Biomedicals,
Santa Ana, California, USA). The MP HEV IgG and IgM EIA test system
was chosen for our analysis on the basis of own round robin test and
due to recently reported comparative analysis of commercial available
HEV IgG/IgMEIA assays showing no inconsistent performances of sensi-
tivity and speciﬁcity among different assays including the MP EIA
(Avellon et al., 2015; Wu et al., 2013).2.4. HEV-RNA Detection
Viral RNAwas isolated from serum obtained from patients and con-
trols (QIAamp Viral RNA Mini Kit; Qiagen GmbH, Hilden, Germany).
HEV-RNA was reverse transcribed into cDNA (QuantiTect Reverse
Transcription Kit; Qiagen GmbH, Hilden, Germany). Presence of
HEV-RNA was examined in all the patients and controls using a
nested PCR assay. Primers were designed based on conserved re-
gions of the overlapping HEV ORF1 region. Outer primer pairs were
HEV-38 (sense) 5′-GAGGCYATGGTSGAGAARG-3′ and HEV-39 (anti-
sense) 5′-GCCATGTTCCAGACRGTRTTCC-3′; inner primers were HEV-
37 (sense) 5′-GGTTCCGYGCTATTGARAARG-3′ and HEV-27 (antisense)
5′-TCRCCAGAGTGYTTCTTCC-3′.
PCR ampliﬁcation was carried out in 25 μl volumes [5 ng viral cDNA,
1× PCR buffer (20 mM Tris–HCl, 50 mM KCl, 2 mM MgCl2), 0.2 mM
dNTPs, 0.4 mMMgCl2, 0.6 μM speciﬁc primer pairs, 1 unit Taq polymer-
ase (Qiagen GmbH, Hilden, Germany)]. Cycling parameters were dena-
turation (94 °C, 5 min), 35 cycles of 30 s at 94 °C denaturation, 30 s at
54 °C annealing, 30 s at 72 °C extension, followed by ﬁnal extension of
10 min (72 °C). Parameters for nested PCR were: denaturation (94 °C
5 min), followed by 40 cycles of 30 s at 94 °C denaturation, 30 s at
56 °C annealing temperature, 30 s at 72 °C extension, followed by
10 min extension (72 °C). A plasmid containing HEV cDNA served as
positive control. Amplicons (306 bp) were visualized on 1.5% agarose
gels stained with SYBR green.
In addition, the HBV patients were conﬁrmed for the presence of
HEV-RNA by applying the same PCR conditions by, however, using
other set of primers which ampliﬁed a 497 bp ORF2 fragment. Outer
primers were HEV-34 (sense) 5′-CCGACGTCYGTYGAYATGAA-3′ and
HEV-36 (antisense) 5′-TTRTCCTGCTGAGCRTTCTC-3′; inner primers
were HEV-35 (sense) 5′- AAGTGAGCGCCTACAYTAYCG-3′ and HEV-29
(antisense) 5′-CTCGCCATTGGCTGAGAC-3′.2.5. HEV Genotyping
PCR products were puriﬁed (Exo-SAP-IT kit; USB, Affymetrix, USA)
and used as sequencing templates (BigDye terminator v.1.1 sequencing
kit; Applied Biosystems, USA, ABI 3130XL sequencer). HEV genotyping
was performed by phylogenetic analyses based on the ampliﬁed ORF2
sequences using the MEGA 5 software (www.megasoftware.net). HEV
reference sequences were obtained from the NCBI GenBank database.
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Analyses were performed using the SPSS software (SPSS Statistics,
IBM, Armonk, NY) and Intercooled Stata (Stata Corporation, College
Station, TX, USA). Prevalences and quantitative variables are given as
percentages and medians with ranges. Categorical variables were com-
pared applying Chi square or Fisher's exact tests. Kruskal–Wallis or
Mann–Whitney U tests were used to compare quantitative
variables. A logistic regression model was used to compare HEV
seroprevalences between groups and to analyze associations of
HEV seroprevalences with disease progression. Odds ratios (OR) and
95% conﬁdence intervals (CI) were calculated. The level of signiﬁcance
was P b 0.05.
3. Results
3.1. Demographic and Clinical Characteristics of Hepatitis B Patients and
Controls
The baseline characteristics of the 1318 Vietnamese hepatitis B
patients and 340 healthy controls are provided in Table 1. The pro-
gression of liver disease increased according to median age of pa-
tients. Most patients were male (82%). Differences of means were
observed for several clinical parameters, including white and red
blood cell counts, platelets, AST/ALT, total and direct bilirubin, albu-
min, prothrombin, AFP and HBV viral loads. Platelet counts were
lower in patients with LC compared to non-LC patients (P b 0.001).
Levels of AST, ALT and total and direct bilirubin were higher in AHB
patients compared to other subgroups (P b 0.001). Albumin and
prothrombin levels were lower in patients with LC and/or with
HCC (P b 0.001). As expected, AFP levels were higher in HCC com-
pared to non-HCC patients (P b 0.001). HBV viral loads were higher
in chronic hepatitis B patients without LC and/or HCC than in chronic
hepatitis B patients with LC and/or HCC (Table 1).
3.2. Seroprevalence of HEV Infection in Patients With HBV Infection and in
Healthy Population
Seroprevalence rates of anti-HEV IgG were higher in patients (45%)
compared to controls (31%) (P=0.034).When stratiﬁed for the clinical
subgroups of HBV infection, the anti-HEV IgG seroprevalence was 42%
(11/26) in AHB, 41% (305/744) in CHB, 52% (83/160) in LC, 48%
(79/166) in HCC and 49% (108/222) in patients with LC and HCCTable 1
Demographic and clinical characteristics of the studied HBV patients and controls.
Characteristics AHB (n = 26) CHB (n = 744) LC (n =
Age (years) 34 [20–49] 41 [9–84] 57 [15–
Gender (M/F) 21/5 557/187 135/25
WBC⁎ (103/ml) NA 6.5 [4–17] 5.6 [1.7–
RBC⁎ (106/ml) NA 4.9 [3–6.8] 4.2 [1.9–
PLT⁎ (103/ml) NA 223 [19–401] 90 [3.7–
AST⁎ (IU/l) 1064.5 [316–4425] 44 [14–1600] 76.5 [15
ALT⁎ (IU/l) 1125.5 [309–3328] 48 [8–2924] 58.5 [8–
Total bilirubin⁎ (μmol/l) 184.8 [21.8–558] 15 [4.9–452] 31 [4.1–
Direct bilirubin⁎ (μmol/l) 137.9 [15–353] 5 [1–298] 12 [0.4–
Albumin⁎ (g/l) 36 [27–42] 41.8 [26–48] 34 [20–
Prothrombin⁎
(% of standard)
70 [58–127] 93 [45–215] 56.5 [13
HBV viral load⁎
(copies/ml)
8.8 × 103
[1062–3.7 × 104]
1.1 × 106
[189–4.3 × 1012]
6.8 × 10
[180–4.
Alpha-feto protein
(AFP)⁎ (mg/l)
NA 4.3 [1–200] 7.3 [1.18
AHB: acute hepatitis B; CHB: chronic hepatitis B; LC: liver cirrhosis; HCC: hepatocellular carcinom
alanine amino transferase; IU: international unit; NA: not available. Values given are medians
⁎ P b 0.001 for comparison with all other groups.(Fig. 1A, Supplementary Table 1). Anti-HEV IgM was observed in
19% (30/160) of LC patients, followed by 15% (4/26) of AHB patients,
15% (33/222) of patients with both LC and HCC, 12% (20/166) of HCC
patients, 9% (65/744) of CHB patients and 5% (16/340) of controls.
The seroprevalence rate of anti-HEV IgM was also higher among pa-
tients with HBV infection (11.6%) compared to the controls (4.7%; ad-
justed P= 0.005) (Fig. 1A, Supplementary Table 1). In the HBV group
positive for anti-HEV IgG, we observed a higher positivity of anti-
HEV IgM in the AHB (36%) and LC (36%) subgroups, followed by
patients with both LC and HCC (29%), HCC (20%) and CHB (20%)
(Fig. 1B).
3.3. Association of Higher HEV Seroprevalence With Increasing Age
Seroprevalences of anti-HEV IgG and IgMwere higher in elder com-
pared to younger subgroups of HBV patients and controls. In the HBV
group, the mean age of patients positive for anti-HEV antibodies was
higher than that in HBV patients negative for anti-HEV antibodies
(P b 0.001 and P=0.002 for anti-HEV IgG and IgM). A similar trend ap-
plied to the controls (P b 0.001 and P=0.022 for anti-HEV IgG and IgM).
A prevalence of 51% and 46% of anti-HEV IgG was observed in HBV
patients and controls N40 years of age, respectively. The anti-HEV IgG
prevalence in HBV patients between 30 to 40 years was higher com-
pared to that in controls of the same age group (P=0.03). No difference
was seen between HBV patients and controls b30 years of age (Fig. 1C
and Supplementary Table 2). The prevalence of anti-HEV IgM in HBV
patients and in controls N40 years of age was 13.7% and 9.2%, respec-
tively. When stratiﬁed for age groups and sex, no differences of anti-
HEV IgM prevalence was observed between HBV patients and controls
(Fig. 1D and Supplementary Table 2).
3.4. HEV Seroprevalence and Progression of HBV-Related Liver Diseases
We found higher anti-HEV IgM prevalences in LC patients (16.8%)
compared to patients without LC (9.5%) (OR = 1.64; 95% CI = 1.1–
2.4; adjusted P = 0.01), indicating that anti-HEV IgM was associated
with LC in chronic hepatitis B patients (Table 2). Signiﬁcance did not
apply to anti-HEV IgG seroprevalences. A similar trend was found
when comparing anti-HEV IgG and IgM prevalences between HCC and
non-HCC patients (Supplementary Table 3).
To analyze associations of HEV seroprevalences with underlying LC
and its prognosis, we categorized LC patients into three subgroups
based on Child–Pugh scores. Anti-HEV IgG prevalences in Child-B and160) HCC (n = 166) LC and HCC (n = 222) Healthy controls
(n = 340)
84] 55 [15–81] 59 [26–81] 33 [15–69]
159/7 210/12 223/117
20.5] 6.3 [3–16] 6 [2.5–17] Normal
9.2] 4.7 [2.1–6.8] 4.3 [2.2–6.2] Normal
441] 208 [68.6–389] 122 [34–361] Normal
–1221] 48.5 [17–2158] 72 [14–670] b30
1426] 40.5 [10–832] 54.5 [10–805] b30
690] 14 [5–160] 22 [7–419] b17
440] 4.9 [1–80] 8.2 [0.4–214] b5
47] 39 [27–49] 37 [24–47] N35
–101] 88 [43–172] 75 [19.6–158] N70
4
7 × 109]
8.56 × 105
[450–1.44 × 109]
5.85 × 104
[190–3.04 × 1010]
NA
–300] 196 [1.1–305] 170 [1.6–880] NA
a;WBC:white blood cells; RBC: red blood cells; PLT: platelets; AST andALT: aspartate and
and range.
Fig. 1. Seroprevalence of HEV infection in patients with HBV infection and in healthy population. (A): Anti-HEV IgG and anti-HEV IgM in healthy controls (HC) and in HBV patients includ-
ing acute hepatitis B (AHB), chronic hepatitis B (CHB), patients with only liver cirrhosis (LC), patients with only hepatocellular carcinoma (HCC) and patients with both LC and HCC; (B):
Anti-HEV IgM positivity in individuals positive for anti-HEV IgG; (C): Anti-HEV IgG seroprevalence increasing with age; (D): Anti-HEV IgM prevalence in different age groups. P values
were calculated by Chi square or Fisher's exact tests for comparisons of the seroprevalence among different groups.
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(adjusted P b 0.001 and P = 0.002, respectively). A similar result was
observed for anti-HEV IgM (adjusted P= 0.007 and P b 0.001, respec-
tively) (Table 2), indicating that higher seroprevalences of anti-HEV
IgG and IgM are associated with an increase of LC severity.3.5. Signiﬁcance of HEV Coinfection in the Outcome of HBV Patients
To analyze the signiﬁcance of HEV superinfection in HBV pa-
tients, we categorized HBV patients into three subgroups based
on HEV serology results. Patients negative for anti-HEV IgG and
IgM were categorized as “no HEV infection”. Patients who were
positive for anti-HEV IgG and negative for IgM were categorized
as “past HEV infection”. “Current HEV infection” was deﬁned as
HBV patients positive for anti-HEV IgM (anti-HEV IgG positive or
negative). Levels of AST, total and direct bilirubin and HBV-DNA
viral loads were elevated in the “current HEV infection” group com-
pared to the “no HEV infection” and “past HEV infection” groups
(P = 0.023 for AST, P = 0.01 for total bilirubin, P = 0.005 for direct
bilirubin, P = 0.026 for HBV-DNA viral loads) (Fig. 2). In contrast,
levels of albumin, prothrombin and platelet counts in the “current
HEV infection” group were lower compared to the “no HEVTable 2
Association of HEV seroprevalence with liver cirrhosis (LC) and prognosis of LC in HBV patient
Patient group
Anti-HEV IgG
Total n Positive n (%) OR (95% CI) P val
Cirrhosis status
Non-cirrhosis 936 395 (42.2) 1 Refer
Cirrhosis 382 191 (50) 0.94 (0.7–1.22) 0.65
Child–Pugh
Child A 235 91 (38.7) 1 Refer
Child B 117 79 (67.5) 3.3 (2.05–5.2) b0.00
Child C 30 9 (70) 1.9 (1.3–2.9) 0.002
Non-cirrhosis: HBV patients without liver cirrhosis; Cirrhosis: hepatitis B patients with liver cir
culated by using logistic regression model and adjusted for age and gender.infection” and “past HEV infection” groups (P b 0.001 for albumin
and prothrombin, P = 0.018 for platelets) (Fig. 2).
We formed three subgroups of patients with “no HEV infection”,
“past HEV infection” and “current HEV infection” for each patient
group including AHB, CHB, LC, HCC and patients with both LC and
HCC. We observed that AST levels were increased, while prothrombin
levels were decreased in the “current HEV infection” patients in CHB
group (P = 0.01) and for other clinical parameters no differences
were observed (Fig. 3).
3.6. Prevalence of HEV-RNA and Sequencing Analysis of HEV Isolates
HEV-RNA was detected in only one serum sample from a patient
with both LC and HCC. The phylogenetic analysis revealed that the
HEV isolate was close to a HEV genotype 3 (NCBI #ssID 1825526)
(Supplementary Fig. 1). The patient was negative for both anti-HEV
IgG and IgM, indicating that he was in the early phase of HEV infection.
4. Discussion
HEV superinfection in HIV-infected patients, but also in patients
with chronic HBV and HCV infections may aggravate the course of un-
derlying conditions (Dalton, 2012; Pischke et al., 2014). We describes.
Anti-HEV IgM
ue Total n Positive n (%) OR (95% CI) P value
ence 936 98 (9.5) 1 Reference
382 64 (16.8) 1.64 (1.1–2.4) 0.01
ence 235 25 (10.6) 1 Reference
01 117 31 (21.4) 2.3 (1.3–4.3) 0.007
30 14 (46.4) 2.7 (1.8–4.2) b0.0001
rhosis (with or without hepatocellular carcinoma); odds ratio (OR) and P values were cal-
Fig. 2. Clinical outcomes of HEV superinfection inHBV patients. Based on the positivity of anti-HEV IgG and anti-HEV IgM, HBV patients were categorized into three different groups as “no
HEV infection”, “past HEV infection” and “current HEV infection”. Different clinical and biochemical parameters including AST (A), ALT (B), albumin (C), total bilirubin (D), direct bilirubin
(E), prothrombin (F), platelets (G) and HBV-DNA viral loads (H) were compared. Box-plots illustrate medians with 25 and 75 percentiles and P values were calculated by using Kruskal–
Wallis test. The number in parenthesis indicates number of samples analyzed and those numbers in the respective groups vary for the clinical parameters because some patients were not
tested for all the clinical parameters.
Fig. 3. Clinical outcomes of HEV superinfection in patients with chronic HBV. HBV patients were categorized into three different groups as “no HEV infection”, “past HEV infection” and
“current HEV infection” based on the positivity of anti-HEV IgG and anti-HEV IgM. The levels of aspartate aminotransferase (AST) (A) and prothrombin (B) were compared. Box-plots il-
lustrated medians with 25 and 75 percentiles and P values were calculated by using Kruskal–Wallis test. The number in parenthesis indicates number of analyzed subject samples.
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compared to healthy individuals. The frequency of HEV superinfection
in HBV patients was differentially distributed among progressive stages
of HBV infection. HEV infection was independently associated with the
prognosis of HBV-related LC and the clinical outcome of HBV infection.
HEV seroprevalences have previously been determined in general
populations and blood donors from various geographical settings
(Boutrouille et al., 2007; Cleland et al., 2013; Gallian et al., 2014; Guo
et al., 2010; Hau et al., 1999; Pittaras et al., 2014; Ren et al., 2014). Our
study shows prevalences of 31% and 5%of anti-HEV IgGand IgM, respec-
tively, in healthy Vietnamese individuals. Anti-HEV IgG seropositivity
was considerably higher than previously reported in rural areas of
Vietnam (Hau et al., 1999). This differencemight result from the sen-
sitivity and speciﬁcity of ELISA tests applied (Abravanel et al., 2014;
Mansuy et al., 2011). Comparative analysis of the sensitivity and
speciﬁcity of commercial test systems have been described in recent
reports showing comparable performance in terms of negative pre-
dictive value and slightly variable performance in relation to sensi-
tivity and speciﬁcity (Avellon et al., 2015; Pas et al., 2013; Wenzel
et al., 2013; Wu et al., 2014). In our study, the used MP HEV EIA
showed minor limitation with regard to sensitivity (IgM and IgG,
approx. 80% and approx. 75%, respectively) in agreement to recent
reports. However, the MP HEV EIA assay seemed to be robust and
suitable for our analysis generating a feasible and true number of
positive HEV IgM and IgG samples. Social and demographic charac-
teristics may also cause differences of seroprevalences (Hau et al.,
1999; Mansuy et al., 2011). Our results support studies in Chinese
blood donors, where anti-HEV IgG and IgM prevalences were approxi-
mately 30% and 1%, respectively (Guo et al., 2010; Ren et al., 2014).
Somewhat lower anti-HEV IgG prevalences of 3% to 17% occur among
most European populations (Beale et al., 2011; Boutrouille et al., 2007;
Cleland et al., 2013; Gallian et al., 2014; Juhl et al., 2014; Pittaras et al.,
2014; Ren et al., 2014). HEV seroprevalenceswere, however, exception-
ally high in southern France (53%) and Denmark (21%) (Christensen
et al., 2008; Mansuy et al., 2011).
This is the ﬁrst study on HEV superinfection in Vietnamese HBV pa-
tients. Prevalences of anti-HEV IgG and IgM in patients were 45% and
12%, respectively. The HEV seroprevalence in our patient group differed
from other studies on HBV, HCV and HIV infections (Atiq et al., 2009;
Bayram et al., 2007; Feldt et al., 2013; Hamid et al., 2002). Anti-HEV
IgG prevalences in chronic HBV Turkish and American patients were
14% and 8% (Atiq et al., 2009; Bayram et al., 2007). In agreement with
other ﬁndings (Atiq et al., 2009), our results indicate that the HEV sero-
prevalence was higher in patients with HBV-related liver diseases com-
pared to healthy individuals, suggesting patients with HBV-related liver
diseases might have a higher risk for HEV infection (Hamid et al., 2002).
Nevertheless, similar ﬁndings were not observed in other studies
(Bayram et al., 2007; Hamid et al., 2002). A probable explanation
could be the sample size utilized in these studies and the study area.
These both factors may largely contribute for such dissimilarities in se-
roprevalence rates. In Europe, HEV infection was observed to be higher
in autoimmune hepatitis patients and not in patients with either chron-
ic hepatitis B or C (Pischke et al., 2014), whereas in endemic areas like
Vietnam, individuals usually acquire the HBV early in their life and
HEV infection subsequently through the fecal–oral transmission later.
A plausible explanation is that the patients primarily infected with
HBV may show an altered immune response and thus likely to be
more susceptible for HEV as a secondary infection. In addition, HEV su-
perinfection in HIV patients and development of chronic hepatitis E has
also been described (Dalton et al., 2009). Recently, a study has found a
seroprevalence of anti-HEV IgG in Ghana (45%) and Cameroon (14%)
(Feldt et al., 2013). However, no contribution of HEV infection to liver
pathology was observed. The HEV seroprevalence in our study group
was signiﬁcantly associatedwith age, both in HBV patients and controls,
indicating cumulative exposure to HEV. Aging of the immune system
might also favor acquisition of HEV infection.Althoughmost HEV-infected individuals are asymptomatic, the out-
come of HEV superinfection in HBV patients appears more severe
(Cheng et al., 2013; Marion-Audibert et al., 2010; Monga et al., 2004).
Our results show increased levels of liver enzymes and total and direct
bilirubin and decreased levels of albumin, prothrombin and platelet
counts in HBV patients with concomitant HEV infection. In contrast to
an earlier study suggesting that chronic HBV infections may be inactive
during HEV–HBV coinfections (Cheng et al., 2013), we found higher
HBV-DNA loads in coinfections. Biochemical and serological tests sug-
gest that HEV superinfection contributes to inﬂammation and liver fail-
ure. HBV-DNA loadswere lower inHBVpatientswith past HEV infection
compared to thosewith no or patentHEV infection, suggesting that host
immune responses contribute to control HBV replication. HBsAg posi-
tive individuals had a poorer prognosis after HEV superinfection
(Chow et al., 2014; Wu et al., 2013).
Although associations of HEV infection with development and pro-
gression of LC were reported (Gerolami et al., 2008; Kumar et al.,
2007; Marion-Audibert et al., 2010), the mechanisms of LC induction
are unclear. According to previous studies, we show that HEV infections
were independently associated with underlying LC and progression in
chronic hepatitis B. Hepatocyte damage and immune responses during
HEV superinfection that leads to increased liver inﬂammation can
progress to LC. The severity of LC is classiﬁed based on the Child–
Pugh score, determined by a number of clinical and laboratory pa-
rameters such as bilirubin, albumin, and prothrombin levels. The as-
sociation of HEV superinfection with increased abnormalities of
bilirubin, albumin, and prothrombin levels supports that HEV super-
infection contributes to severity of HBV infection. Although the dif-
ference was not signiﬁcant, the prevalence of anti-HEV antibodies
was increased among patients with HBV-related HCC. Therefore, tu-
morigenesis of HEV cannot be excluded.
In this study, we detected the presence of HEV-RNA in only one
serum sample from patient with both LC and HCC (negative for both
anti-HEV IgG and IgM) showing that this patient was in the early
stage of HEV infection. However, we could not follow up longitudinally
the patient conﬁrmed positive for HEV-RNA to verify the chronicity of
HEV infection. HEV-RNA can persist longer in the stool than in the
blood (Kamar et al., 2012), therefore another limitation of the study is
that the nested PCR for detection of HEV-RNA from stool of the HBV pa-
tients and controls had not been performed due to the unavailability of
stool samples.
In conclusion, this study indicates high HEV seroprevalences in
Vietnamese patients with HBV-related liver diseases and in healthy
individuals. HEV infection may aggravate the clinical outcome of HBV
infection, especially in liver cirrhosis.
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